Document:

Exhibit 10.1

 Exhibit 10.1 

TERMINATION AGREEMENT 

AMONG 
 FEDERAL DEPOSIT
INSURANCE CORPORATION, 
 RECEIVER OF EUROBANK 

SAN JUAN, PUERTO RICO 

FEDERAL DEPOSIT INSURANCE CORPORATION 

and 
 ORIENTAL BANK

 SAN JUAN, PUERTO RICO 

DATED AS OF 

FEBRUARY 6, 2017 

 TERMINATION AGREEMENT 

THIS TERMINATION AGREEMENT (the “Agreement”), is made and entered into as of the 6th day of February, 2017, by and among the FEDERAL DEPOSIT INSURANCE CORPORATION, as RECEIVER OF EUROBANK, SAN JUAN, PUERTO RICO (the “Receiver”), ORIENTAL BANK,
organized under the laws of the Commonwealth of Puerto Rico and having its principal place of business in San Juan, Puerto Rico (the “Assuming Institution”), and the FEDERAL DEPOSIT INSURANCE CORPORATION, organized under the laws of
the United States of America and having its principal office in Washington, D.C., acting in its corporate capacity (the “Corporation”), The Receiver, the Corporation and the Assuming Institution may each be referred to herein as a
“Party” or collectively as the “Parties”. 
 RECITALS 

 

	A.	The Receiver, Oriental Bank and Trust and the Corporation entered into a P&A Agreement dated as of April 30, 2010 with respect to certain assets and liabilities of EuroBank (“Failed Bank”);

  

	B.	The P&A Agreement includes a Single Family Shared-Loss Agreement as Exhibit 4.15A (“SFSLA”) and a Commercial Shared-Loss Agreement as Exhibit 4.15B (“CSLA”). 

 

	C.	Oriental Bank and Trust changed its name to Oriental Bank in January 2013. 

  

	D.	The Receiver, Oriental Bank and the Corporation desire to terminate the SFSLA and the CSLA (the SFSLA and the CSLA collectively, the “Shared-Loss Agreements”). 

NOW, THEREFORE, in consideration of the mutual promises herein set forth and other valuable consideration, the parties hereto agree as
follows: 
 ARTICLE I  

CLOSING 
 Except as
noted below in Section 2.1 and subject to the satisfaction, or waiver in writing of the conditions precedent set forth in Article III, the transactions contemplated by this Agreement shall be consummated at a closing (the “Closing”)
to be held in person or by electronic means, as the Receiver shall direct, on February 6, 2017, or such earlier or later date, or in such other manner, as the parties hereto may agree in writing (the “Closing Date”). 

  
 2 

 ARTICLE II 

PAYMENTS AND TERMINATION 

2.1 Payment of Termination Amount. Within two Business Days after the Closing Date, subject to the satisfaction or waiver in
writing of the conditions precedent set forth herein, the Assuming Institution shall pay or cause to be paid to the Receiver by wire transfer in immediately available funds, Ten Million One Hundred Twenty Four Thousand Six Hundred Ninety Eight
Dollars ($10,124,698) (the “Termination Amount”). The Assuming Institution and the Receiver hereby acknowledge that the amount of shared-loss claims filed by the Assuming Institution but not yet paid by the Receiver were accounted for in
the calculation of the Termination Amount. 
 2.2 Termination of the Shared-Loss Agreements. Upon the occurrence of the
Closing and subsequent payment of the Termination Amount all rights and obligations of the parties to make and receive payments pursuant to the Shared-Loss Agreements and all rights and obligations of the parties thereto, shall terminate effective
as of the Closing Date. 
 2.3 Legal Action; Utilization of Special Receivership Powers. As of the Closing Date, the Assuming
Institution’s right, under Article III of each of the Shared-Loss Agreements, to request to utilize any special legal power or right which the Assuming Institution derived as a result of having acquired an asset from the Receiver shall
terminate; provided, however, any prior requests to utilize such special powers or rights that were granted by the Receiver shall not be affected hereby, and the Assuming Institution may continue to use such special legal rights or powers in the
litigation in which the permission to use those special legal powers or rights was given. Notwithstanding the foregoing, the Assuming Institution shall continue to have all rights and remedies available to it under applicable state and federal laws,
which shall not be limited or altered by this Agreement. 
 ARTICLE III 

CONDITIONS PRECEDENT 

The obligations of the parties to this Agreement are subject to the Receiver and the Corporation having received at or before the Closing Date
evidence reasonably satisfactory to each of any necessary approval, waiver, or other action by any governmental authority, the board of directors of the Assuming Institution, or other third party, with respect to this Agreement and the transactions
contemplated hereby, and any agreements, documents, matters or proceedings contemplated hereby or thereby. 

  
 3 

 ARTICLE IV 

MISCELLANEOUS 

4.1 No Third Party Beneficiary. Nothing expressed or referred to in this Agreement is intended or shall be construed to give any
Person other than the Receiver, the Corporation and right, remedy or claim under or with respect to this Agreement or any provisions contained herein, it being the intention of the parties hereto that this Agreement, the obligations and statements
of responsibilities hereunder, and all other conditions and provisions hereof are for the sole and exclusive benefit of the Receiver, the Corporation and the Assuming Institution and that there be no other third party beneficiaries. 

4.2 Rights Cumulative. Except as otherwise expressly provided herein, the rights of each of the parties under this Agreement are
cumulative, may be exercised as often as any party considers appropriate and are in addition to each such party’s rights under this Agreement, any of the agreements related thereto or under applicable law. Any failure to exercise or any delay
in exercising any of such rights, or any partial or defective exercise of such rights, shall not operate as a waiver or variation of that or any other such right, unless expressly otherwise provided, 

4.3 Entire Agreement. This Agreement embodies the entire agreement of the parties hereto in relation to the subject matter
herein and supersedes all prior understandings or agreements, oral or written, between the parties. 
 4.4
Counterparts. 
 (a) This Agreement may be executed in any number of counterparts and by the duly
authorized representative of a different party hereto on separate counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same Agreement. 

(b) Each counterpart of this Agreement will be treated in all manner and respects as an original agreement and will be considered to
have the same binding legal effect as if it were the original signed version thereof delivered in person. No signatory to this Agreement may raise the use of a facsimile machine or other electronic means to deliver an executed document or the fact
that any signature or agreement was transmitted or communicated through the use of a facsimile machine or other electronic means as a defense to the formation or enforceability of a contract and each party hereto forever waives any such defense.

 4.5 GOVERNING LAW. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS HEREUNDER AND THEREUNDER SHALL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE FEDERAL LAW OF THE UNITED STATES OF AMERICA, AND IN THE ABSENCE OF CONTROLLING FEDERAL LAW, IN ACCORDANCE WITH THE LAWS OF THE COMMONWEALTH IN WHICH THE MAIN OFFICE OF THE FAILED BANK WAS LOCATED. 

4.6 Successors. All terms and conditions of this Agreement shall be binding on the successors and assigns of the Receiver, the
Corporation and the Assuming Institution. 
 4.7 Modification. No amendment or other modification, rescission or release of
any part of this Agreement shall be effective except pursuant to a written agreement subscribed by the duly authorized representatives of the parties hereto. 

  
 4 

 4.8 Manner of Payment. All payments due under this Agreement shall be in lawful
money of the United States of America in immediately available funds as each party hereto may specify to the other parties; provided that in the event the Receiver or the Corporation is obligated to make any payment hereunder in the amount of
$25,000.00 or less, such payment may be made by check. 
 4.9 Waiver. Each of the Receiver, the Corporation and the Assuming
Institution may waive its respective rights, powers or privileges under this Agreement; provided that such waiver shall be in writing; and further provided that no failure or delay on the part of the Receiver, the Corporation or the Assuming
Institution to exercise any right, power or privilege under this Agreement shall operate as a waiver thereof, nor will any single or partial exercise of any right, power or privilege under this Agreement preclude any other or further exercise
thereof or the exercise of any other right, power or privilege by the Receiver, the Corporation, or the Assuming Institution under this Agreement, nor will any such waiver operate or be construed as a future waiver of such right, power or privilege
under this Agreement. 
 4.10 Severability. If any provision of this Agreement is declared invalid or unenforceable, then, to
the extent possible, all of the remaining provisions of this Agreement shall remain in full force and effect and shall be binding upon the parties hereto. 

4.11 Survival of Covenants. The covenants, representations, and warranties in this Agreement shall survive the execution of this
Agreement and the consummation of the transactions contemplated hereunder. 
 4.12 Capitalized Terms. Capitalized terms not
otherwise defined herein shall have the meanings given such terms in the P&A Agreement or the Shared-Loss Agreements, as applicable. 

  
 5 

 

 

  
 6Exhibit 10.1

 

GARTNER, INC.

2014 LONG-TERM INCENTIVE PLAN

STOCK APPRECIATION RIGHT AGREEMENT

 

Grant # SS___

 

NOTICE OF GRANT

 

Gartner, Inc. (the “Company”)
hereby grants you, ______________ (the “Grantee”), a stock appreciation right (the “SAR”) under the Company’s
2014 Long-Term Incentive Plan (the “Plan”), to exercise in exchange for a payment from the Company pursuant to this
SAR. The date of this Agreement is February 6, 2017 (the “Grant Date”). In general, the latest date this SAR will expire
is February 6, 2024 (the “Expiration Date”). However, as provided in Appendix A (attached hereto), this SAR may expire
earlier than the Expiration Date. Subject to the provisions of Appendix A and of the Plan, the principal features of this SAR are
as follows:

 

Number of Shares to which this SAR pertains: 

 

Exercise Price per Share:  $

 

Vesting Schedule:

 

Twenty-five percent (25%) of the Shares to which this SAR pertains
shall vest on each of the first four anniversaries of the date hereof, or February 6, 2018, 2019, 2020 and 2021, subject to Grantee’s
Continued Service through each such date.

 

Your signature below indicates your agreement
and understanding that this SAR is subject to all of the terms and conditions contained in the Plan and this SAR Agreement (the
“Agreement”), which includes this Notice of Grant and Appendix A. For example, important additional information on
vesting and termination of this SAR is contained in Paragraphs 3 through 5 of Appendix A, and there is a non-competition covenant
in Paragraph 17. ACCORDINGLY, PLEASE BE SURE TO READ ALL OF APPENDIX A, WHICH CONTAINS THE SPECIFIC TERMS AND CONDITIONS OF
THIS SAR.

 

	GARTNER, INC.	 	GRANTEE

 

	By:	 	 	 	 

Eugene A. Hall, CEO

    	 

    	

    

APPENDIX A

TERMS AND CONDITIONS OF STOCK APPRECIATION
RIGHTS

 

1.       Grant of SAR. The Company hereby
grants to the Grantee under the Plan, as a separate incentive in connection with his or her employment and not in lieu of any salary
or other compensation for his or her services, a Stock Appreciation Right (“SAR”) pertaining to all or any part
of an aggregate of Shares shown on the attached Notice of Grant, which SAR entitles the Grantee to exercise the SAR in exchange
for Shares in the amount determined under Paragraph 9 below; provided, however, that should Grantee’s Continued
Service end at any time during the calendar year in which the grant was made, then the number of Shares to which this SAR pertains
will be pro-rated to the number of days in that year in which the Grantee was employed (e.g., for the avoidance of doubt,
the number of Shares will equal the number specified in the Notice of Grant, multiplied by the number of days from January 1 to
the date of termination, divided by 365).

 

2.       Exercise Price. The purchase price
per Share for this SAR (the “Exercise Price”) shall be $99.07, which is the Fair Market Value of a Share on
the Grant Date. When the SAR is exercised, the purchase price will be deemed paid by the Grantee for the exercised portion of the
SAR through the past services rendered by the Grantee, and will be subject to the appropriate tax withholdings.

 

3.       Vesting Schedule. Except as otherwise
provided in this Agreement, the right to exercise this SAR will vest in accordance with the vesting schedule set forth in the Notice
of Grant which constitutes part of this Agreement. Shares scheduled to vest on any date will vest only if the Grantee remains in
Continued Service on such date. Should the Grantee’s Continued Service end at any time (the “Termination Date”),
any unvested portion of this SAR will be immediately cancelled; provided, however, that if termination of Continued Service
results from the Grantee’s death, Disability or Retirement, then any unvested portion of this SAR shall vest as follows:

 

		(a)	If termination of Continued Service is due to the Grantee’s death or Disability, the unvested portion of this SAR shall
vest in full on the Termination Date;

 

		(b)	If termination of Continued Service is due to Retirement and the Grantee is less than age 60, the unvested portion of this
SAR that would have vested by its terms within twelve (12) months from the Termination Date shall continue to vest as set forth
in the Notice of Grant despite the termination of service;

 

		(c)	If termination of Continued Service is due to Retirement and the Grantee is age 60 on the Termination Date, the unvested portion
of this SAR that would have vested by its terms within twenty-four (24) months from the Termination Date shall continue to vest
as set forth in the Notice of Grant despite the termination of service;

 

		(d)	If termination of Continued Service is due to Retirement and the Grantee is age 61 on the Termination Date, the unvested portion
of this SAR that would

    	-2-

    	

    

	 	 	have vested by its terms within
thirty-six (36) months from the Termination Date shall continue to vest as set forth in the Notice of Grant despite the termination
of service; and
	 	 	 
		(e)	If termination of Continued Service is due to Retirement
and the Grantee is age 62 or older on the Termination Date, the entire unvested portion of this SAR shall continue to
vest as set forth in the Notice of grant despite the termination of Service;

 

provided further, however,
that Grantee is in full compliance with all the terms of this Agreement at the time of vesting. The Committee, in its discretion,
may accelerate the vesting of the balance, or some lesser portion of the balance, of the SARs at any time, subject to the terms
of the Plan. If so accelerated, such SARs will be considered as having vested as of the date specified by the Committee.

 

4.       Termination of SAR. In the event
of the Grantee’s termination of Continued Service for any reason other than Retirement, Disability or death, the Grantee
may, within ninety (90) days after the date of such termination of Continued Service (excluding any period during which Grantee
is prohibited from trading under the Company’s Insider Trading Policy), or prior to the Expiration Date, whichever shall
first occur, exercise any vested but unexercised portion of this SAR. In the event of the Grantee’s termination of Continued
Service due to Disability or death, the Grantee may, within twelve (12) months after the date of such termination, or prior to
the Expiration Date, whichever shall first occur, exercise any vested but unexercised portion of this SAR. In the event of the
Grantee’s termination of Continued Service due to Retirement, the Grantee may exercise any vested but unexercised portion
of this SAR through the Expiration Date.

 

5.       Death of Grantee. In the event
that the Grantee dies while in the employ of the Company and/or a parent of the Company or Subsidiary, the administrator or executor
of the Grantee’s estate (or such other person to whom the SAR is transferred pursuant to the Grantee’s will or in accordance
with the laws of descent and distribution), may exercise any vested but unexercised portion of the SAR in accordance with Paragraph
4 above. Any such transferee must furnish the Company (a) written notice of his or her status as a transferee, (b) evidence satisfactory
to the Company to establish the validity of the transfer of this SAR and compliance with any laws or regulations pertaining to
such transfer, and (c) written acceptance of the terms and conditions of this SAR as set forth in this Agreement.

 

6.       Persons Eligible to Exercise SAR.
Except as provided in Paragraph 5 above or as otherwise determined by the Committee in its discretion, this SAR shall be exercisable
during the Grantee’s lifetime only by the Grantee.

 

7.       SAR is Not Transferable. Except
to the limited extent provided in Paragraph 5 above, this grant and the rights and privileges conferred hereby shall not be transferred,
assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to sale under
execution, attachment or similar process. Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this
grant, or of any right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process,
this grant and the rights and

    	-3-

    	

    

privileges conferred hereby immediately shall
become null and void. Notwithstanding the preceding, the Grantee may transfer (not for consideration and for bona fide estate planning
purposes) the Stock Appreciation Rights awarded under this Agreement to a revocable estate planning trust that is established solely
for the benefit of Grantee and his or her immediate family. Any such transfer will be permitted only if it is in compliance with
such rules and procedures as the Company may establish from time to time. Among other things, Grantee must acknowledge and agree
that (a) for U.S. income tax purposes, all taxable income from the Stock Appreciation Rights will be reported to Grantee alone,
(b) if Grantee proposes to change the nature or character of the transferee trust, Grantee first must inform the Company and the
Company may require that the Stock Appreciation Rights be transferred back to Grantee alone, and (c) no additional other or further
transfers of the Stock Appreciation Rights will be permitted under any circumstance.

 

8.       Exercise of SAR. This SAR may be
exercised by the person then entitled to do so as to any Shares, and such exercise must be in accordance with the Company’s
published exercise procedures, as in effect from time to time, which may require the Grantee to exercise this SAR through the Company’s
designated broker or administrator. All exercises must be accompanied by payment of the aggregate exercise price together
with all taxes the Company determines are required to be withheld by reason of the exercise of this SAR or as are otherwise required
under Paragraph 10 below. Exercise forms are available from the Stock Plan Administration. Payment of the aggregate exercise price
must be (i) in cash (including check, bank draft or money order), or (ii) for “cashless exercises” during the open
trading window, by delivery of such documentation as the Company and any broker of deposit, if applicable, shall require to effect
an exercise of the SAR and delivery to the Company of the sale or loan proceeds required to pay the exercise price, in each case
plus any applicable withholding taxes.

 

9.       Payment of SAR Amount. Upon
exercise of this SAR, the Grantee shall be entitled to receive the number of Shares (the “SAR Amount”), less
applicable withholdings, determined by (i) multiplying (a) the difference between the Fair Market Value of a Share over the Exercise
Price; times (b) the number of Shares with respect to which this SAR is exercised, and (ii) dividing the product of (a) and (b)
by the Fair Market Value of a Share. The SAR Amount shall be paid solely in whole Shares; any fractional amount shall be rounded
down to the nearest whole share. Shares issued pursuant to the exercise of this SAR may be delivered in book form or listed
in street name with a brokerage company of the Company’s choice. For purposes of this Paragraph 9, Fair Market Value has
the same meaning as in the Plan or as otherwise determined by the Company or its delegee.

 

10.     Tax Withholding and Payment Obligations.
When the Shares are issued as payment for exercised SARs, the Grantee will recognize immediate U.S. taxable income if the Grantee
is a U.S. taxpayer. If the Grantee is a non-U.S. taxpayer, the Grantee will be subject to applicable taxes in his or her jurisdiction.
The Company (or the employing parent of the Company or Subsidiary) will withhold a portion of the Shares otherwise issuable in
payment for exercised SARs that have an aggregate market value sufficient to pay the minimum federal, state and local income, employment
and any other applicable taxes required to be withheld by the Company (or the employing parent of the Company or Subsidiary) with
respect to the Shares. No fractional Shares will be withheld or issued pursuant to the exercise of SARs and the issuance of Shares
thereunder. The Company (or the employing parent of the Company or Subsidiary) may instead, in its discretion, withhold an

    	-4-

    	

    

amount necessary to pay the applicable taxes
from the Grantee’s paycheck, with no withholding of Shares. In the event the withholding requirements are not satisfied through
the withholding of Shares (or, through the Grantee’s paycheck, as indicated above), no payment will be made to the Grantee
(or his or her estate) for SARs unless and until satisfactory arrangements (as determined by the Committee) have been made by the
Grantee with respect to the payment of any income and other taxes which the Company determines must be withheld or collected with
respect to such SARs. By accepting this award of SARs, the Grantee expressly consents to the withholding of Shares and to any cash
or Share withholding as provided for in this Paragraph 10. All income and other taxes related to the SAR award and any Shares delivered
in payment thereof are the sole responsibility of the Grantee. In no event will the Company reimburse the Grantee for any taxes
that may be imposed on the Grantee as result of Section 409A.

 

11.     Suspension of Exercisability.
If at any time the Company shall determine, in its discretion, that the listing, registration or qualification of the SARs upon
any securities exchange or under any state or federal law, or the consent or approval of any governmental regulatory authority,
is necessary or desirable as a condition of the exercise of SARs hereunder, this SAR may not be exercised, in whole or in part,
unless and until such listing, registration, qualification, consent or approval shall have been effected or obtained free of any
conditions not acceptable to the Company. The Company shall make reasonable efforts to meet the requirements of any such state
or federal law or securities exchange and to obtain any such consent or approval of any such governmental authority.

 

12.     No Rights of Stockholder. Neither
the Grantee (nor any transferee) shall be or have any of the rights or privileges of a stockholder of the Company in respect of
any of the Shares covered by this SAR.

 

13.     Successors and Assigns. The Company
may assign any of its rights under the Agreement to single or multiple assignees, and this Agreement shall inure to the benefit
of the successors and assigns of the Company. The rights and obligations of the Grantee under this Agreement may be assigned only
with the prior written consent of the Company.

 

14.     No Effect on Employment. The Grantee’s
employment with the Company and any parent of the Company or Subsidiary is on an at-will basis only, subject to the provisions
of applicable law. Accordingly, subject to any written, express employment contract with the Grantee, nothing in this Agreement
or the Plan shall confer upon the Grantee any right to continue to be employed by the Company or any parent of the Company or Subsidiary
or shall interfere with or restrict in any way the rights of the Company or the employing parent of the Company or Subsidiary,
which are hereby expressly reserved, to terminate the employment of the Grantee at any time for any reason whatsoever, with or
without good cause. Such reservation of rights can be modified only in an express written contract executed by a duly authorized
officer of the Company or the parent of the Company or Subsidiary employing the Grantee.

 

15.     Address for Notices. Any notice
to be given to the Company under the terms of this Agreement shall be addressed to the Company, in care of its Secretary at the
Company’s headquarters, P.O. Box 10212, 56 Top Gallant Road, Stamford, CT 06902-7700, or at such other address as the
Company may hereafter designate in writing.

    	-5-

    	

    

16.     Maximum Term of SAR. Notwithstanding
any other provision of this Agreement, this SAR is not exercisable after the Expiration Date.

 

17.     Non-Competition. The Grantee agrees
that, during the Restraint Period (as defined below), for any reason, the Grantee will not engage in any Competitive Act within
the Non-Compete Area. For purposes of this Agreement, “Competitive Act” (independently and collectively) shall
mean any direct or indirect instance of (a) the development, marketing or selling of, or assisting others to develop, market or
sell, research and/or advisory services in the areas of information technology, supply chain management, and/or digital marketing,
regardless of the manner in which such research and/or advisory services are provided, or (b) the solicitation, directly or indirectly,
of the Company’s clients or known prospects for the purposes of developing, digital marketing or selling the products or
services referred to in clause (a), by the Grantee (whether as a consultant, analyst, sales person, independent contractor, agent,
independent business venturer, partner, member, employee or otherwise). “Non-Compete Area” shall mean any jurisdiction
or location in which the Company conducts business or has clients or prospects, including Europe, North America, the USA, the United
Kingdom, Australia, Asia, Asia-Pacific & Japan, Middle East, Central and South America, or Africa. “Restraint Period”
shall mean the period of three (3) years following the last date on which any SARs vest. During the Restraint Period, the Grantee
will notify (in writing and not less than 72 hours in advance) the Company’s General Counsel if he or she intends to become
an employee or other service provider of any entity other than the Company (for example, but not by way of limitation, as an employee,
consultant, analyst, sales person, independent contractor, agent, independent business venturer, partner or member). The Grantee
agrees that the restrictions in this Paragraph 17 will apply as if they consisted of several separate, independent and cumulative
covenants and restraints. Employee further agrees that if any separate covenant and restraint described in this Paragraph 17 is
unenforceable, illegal or void, that covenant and restraint is severed and the other covenants and restraints remain in full force
and effect. It will not be a violation of this Agreement for the Grantee to take an accounting and finance position with an entity
that derives a portion (but less than a majority) of its revenues from Competitive Acts, provided that the Grantee does not engage
in sales, marketing, development, operational or strategic activities related to such Competitive Acts and or the portion of the
New Entity related thereto. It also will not be a violation of this Agreement for the Grantee to take a senior executive position
with an entity (the “New Entity”) so long the New Entity itself does not engage in any Competitive Act, it being
understood that affiliated corporations of the New Entity may engage in Competitive Acts but only if both the group of affiliated
entities that includes the New Entity derives less than a majority of its revenues from Competitive Acts and the Grantee does not
engage in any sales, marketing, development, operational or strategic activities related to such Competitive Acts. Notwithstanding
the foregoing, during the final eighteen (18) months of the Restraint Period, only the following entities and their successors
will be deemed to be engaged in Competitive Acts: Forrester, IDG (inclusive of IDC), Informa (inclusive of Ovum and Datamonitor),
The Advisory Board Company (ABCO), IHS/Markit, Info-Tech Research, ISG (Information Services Group), The 451 Group (inclusive of
Yankee, Uptime Research, etc.), eMarketer, Sirius Decisions, G2Crowd, TechTarget, Apptio, Accenture, UBM, Hackett Group and TrustRadius;
provided, however, that the Company may modify the foregoing list of entities considered to be engaging in Competitive Acts at
any time upon at least thirty (30) days’ written notice to the Grantee.

    	-6-

    	

    

Grantee acknowledges that the time, geographic
and scope limitations of his/her obligations set forth herein are fair and reasonable in all respects, especially in light of the
international scope and nature of the Company’s business, and that Grantee will not be precluded from gainful employment
if he/she is obligated not to compete with the Company or solicit its customers or others during the Restraint Period and within
the Non-Compete Area as described above. In the event of Grantee’s breach or violation of the above restrictions, or good
faith allegation by the Company of his/her breach or violation of the above restrictions, the Restraint Period shall be tolled
until such breach or violation, or dispute related to an allegation by the Company that Grantee has breached or violated the above
restrictions, has been duly cured or resolved, as applicable. Grantee understands that any breach or threatened breach of the above
restrictions will cause irreparable injury and that money damages will not provide an adequate remedy therefor and Grantee hereby
consents to the issuance of an injunction without posting of a bond.

 

18.     Non-Solicitation and No-Hire.
The Grantee agrees that for the duration of the Restraint Period, the Grantee shall not directly or indirectly solicit, induce,
hire, recruit or encourage any of the Company’s employees, agents or contractors to leave their employment or engagement
with the Company, whether on the Grantee’s own behalf or on behalf of any other person or entity. General mass solicitations
of employment that are not directed at the Company or any employee(s) of the Company shall not be prohibited by this Paragraph
18.

 

19.     Binding Agreement. Subject to
the limitation on the transferability of this SAR contained herein, this Agreement shall be binding upon and inure to the benefit
of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.

 

20.     Governing Law. This Agreement
shall be construed in accordance with and governed by the laws of the State of Connecticut, other than its conflicts of laws provisions.

 

21.     Plan Governs. This Agreement is
subject to all of the terms and provisions of the Plan. In the event of a conflict between one or more provisions of this Agreement
and one or more provisions of the Plan, the provisions of the Plan shall govern. Capitalized terms and phrases used and not defined
in this Agreement shall have the meaning set forth in the Plan.

 

22.     Committee Authority. The Committee
shall have all discretion, power, and authority to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are consistent therewith (including, but not limited to, the determination of whether
or not any SARs have vested). All actions taken and all interpretations and determinations made by the Committee in good faith
shall be final and binding upon the Grantee, the Company and all other interested persons, and shall be given the maximum deference
permitted by law. No member of the Committee shall be personally liable for any action, determination or interpretation made in
good faith with respect to the Plan or this Agreement.

 

23.     Electronic Delivery and Acceptance.
The Company, in its sole discretion, may decide to deliver any documents related to Stock Appreciation Rights awarded under the
Plan or future Stock Appreciation Rights that may be awarded under the Plan by electronic means. The Grantee hereby consents to
receive such documents by electronic delivery and agrees to participate

    	-7-

    	

    

in the Plan through any on-line or electronic
system established and maintained by the Company or another third party designated by the Company.

 

24.     Captions. The captions provided
herein are for convenience only and are not to serve as a basis for the interpretation or construction of this Agreement.

 

25.     Agreement Severable. In the event
that any provision in this Agreement shall be held invalid or unenforceable, such provision shall be severable from, and such invalidity
or unenforceability shall not be construed to have any effect on, the remaining provisions of this Agreement.

 

26.     Modifications to the Agreement; Clawback.
This Agreement constitutes the entire understanding of the parties on the subjects covered. The Grantee expressly warrants that
he or she is not executing this Agreement in reliance on any promises, representations, or inducements other than those contained
herein. Except as otherwise provided herein, modifications to this Agreement or the Plan can be made only in an express written
contract executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Agreement,
the Company reserves the right to revise this Agreement as it deems necessary or advisable, in its sole discretion and without
the consent of the Grantee, to avoid imposition of any additional tax or income recognition under Section 409A of the Internal
Revenue Code of 1986, as amended, prior to the actual payment of Shares pursuant to this SAR, provided that such revision would
not materially reduce the economic benefits provided or intended to be provided under this Agreement. Additionally, this Agreement
and the award made hereunder shall be subject to any clawback policy which the Company may adopt from time to time as required
by law or otherwise.

 

27.     Amendment, Suspension, Termination.
By accepting this SAR, the Grantee expressly warrants that he or she has received an SAR to purchase stock under the Plan, and
has received, read and understood a description of the Plan. The Grantee understands that the Plan is discretionary in nature and
may be modified, suspended or terminated by the Company at any time.

 

28.     Defined Terms: Capitalized terms
used in this Agreement without definition will have the meanings provided for in the Plan. When used in this Agreement, the following
capitalized terms will have the following meanings:

 

“Continued Service” means that your
employment relationship is not interrupted or terminated by you, the Company, or any parent or Subsidiary of the Company. Your
employment relationship will not be considered interrupted in the case of: (i) any leave of absence approved in accordance with
the Company’s written personnel policies, including sick leave, family leave, military leave, or any other personal leave;
or (ii) transfers between locations of the Company or between the Company and any parent, Subsidiary or successor; provided,
however, that, unless otherwise provided in the Company’s written personnel policies, in this Agreement or under applicable
laws, rules or regulations, or unless the Committee has otherwise expressly provided for different treatment with respect to this
Agreement, (x) no such leave may exceed ninety (90) days, and (y) any vesting shall cease on the ninety-first (91st)
consecutive date of any leave of absence during which your employment relationship

    	-8-

    	

    

is deemed to continue and will not recommence until
such date, if any, upon which you resume service with the Company, its parent, Subsidiary or successor. If you resume such service
in accordance with the terms of the Company’s military leave policy, upon resumption of service you will be given vesting
credit for the full duration of your leave of absence. Continuous employment will be deemed interrupted and terminated for an Employee
if the Grantee’s weekly work hours change from full time to part time. Part-time status for the purpose of vesting continuation
will be determined in accordance with policies adopted by the Company from time to time, which policies, if any, shall supersede
the determination of part-time status set forth in the Company’s posted “employee status definitions”.

 

“Disability” means total and permanent
disability as defined in Section 22(e)(3) of the Code.

 

“Retirement” means termination of
your employment in accordance with the Company’s retirement policies, as in effect from time to time, if on the date of such
termination (i) you are at least 55 years old and your Continued Service has extended for at least five (5) years, and (ii) the
number of full years in your age and your number of full years of Continued Service total at least 65. By way of illustration,
if you terminate your employment in accordance with the Company’s retirement policies on your 63rd birthday after six (6)
years of Continued Service, your total would be 69 and your termination would be treated as a Retirement; if your Continued Service
had extended for only four (4) years, your total would be 67 but your termination would not be treated as a Retirement since you
would not have met the minimum of five (5) years of Continued Service.

 

Your acceptance of this grant indicates your
agreement and understanding that this grant is subject to all of the terms and conditions contained in the Plan and this Agreement,
which includes the Notice of Grant. Your acceptance of this grant indicates your agreement and understanding that this grant is
subject to all of the terms and conditions contained in the Plan and this Award Agreement, which includes the Notice of Grant and
this Agreement.

 

In addition, by your acceptance of this
Stock Appreciation Right grant and in consideration of such grant, you hereby ratify and reaffirm the “Agreement Regarding
Certain Conditions of Employment” (the “Gartner Agreement”) previously entered into between you and the Company,
including but not limited to the confidentiality and post-employment restrictions on competition set forth therein, and/or you
hereby agree to comply with all of the terms and conditions of the Gartner Agreement, which is posted on the Global “Forms
and Policies” section of Gartner At Work, and is incorporated herein by this reference.

    	-9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]